Karyopharm Therapeutics
KPTI
86 hedge funds and large institutions have $239M invested in Karyopharm Therapeutics in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 37 increasing their positions, 17 reducing their positions, and 6 closing their positions.
16,167% more call options, than puts
Call options by funds: $976K | Put options by funds: $6K
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
118% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 17
9% more funds holding
Funds holding: 79 → 86 (+7)
6% more capital invested
Capital invested by funds: $226M → $239M (+$13.6M)
4.12% more ownership
Funds ownership: 0% → 4.12% (+4.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$13.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.21M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.06M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.83M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$1.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.68M |
| 2 |
Millennium Management
New York
|
-$1.45M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$415K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$265K |
| 5 |
FAAS
First Allied Advisory Services
San Diego,
California
|
-$203K |
KPTI Hedge Fund Activity: Q4 2016 in Review
86 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q4 2016, worth a combined $239M — up 6% from $226M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new KPTI positions and 6 closed out — a net gain of 8 holders — while 37 added to existing stakes and 17 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $13.2M. The largest seller was Fidelity Investments, cutting an estimated $5.68M.
- 86 institutional investors held Karyopharm Therapeutics (KPTI) as of Q4 2016, up from 79 in Q3 2016.
- Funds reported $239M of Karyopharm Therapeutics stock for Q4 2016, up 6% quarter-over-quarter.
- 14 funds opened new Karyopharm Therapeutics positions in Q4 2016 and 6 closed out, a net change of +8 holders.
- The largest Karyopharm Therapeutics buyer in Q4 2016 was Wellington Management Group, an estimated $13.2M added.
- The largest Karyopharm Therapeutics seller in Q4 2016 was Fidelity Investments, an estimated $5.68M sold.
Based on aggregated 13F filings for Q4 2016.